Research and development of antibacterial agents

被引:38
作者
Chopra, I [1 ]
机构
[1] Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England
[2] Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England
关键词
D O I
10.1016/S1369-5274(98)80080-5
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Several new antibacterial agents are currently being developed in response to the emergence df bacterial resistance to existing drugs. The new agents include compounds that inhibit macromolecular synthesis or interfere with bacterial membrane function. Apart from the oxazolidinones and cationic peptides, the remainder of these new compounds are analogues of earlier antibiotic classes; therefore, it is probable that existing resistance mechanisms will adapt to accommodate the new derivatives. To minimise the potential for emergence of resistance to new agents, research strategies should be chosen that not only enhance the discovery of structurally novel drugs, but also direct these to new molecular targets that may themselves have decreased potential to give rise to drug-resistant variants.
引用
收藏
页码:495 / 501
页数:7
相关论文
共 45 条
  • [1] Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues
    Allen, NE
    LeTourneau, DL
    Hobbs, JN
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) : 66 - 71
  • [2] GENETICS AND MECHANISMS OF GLYCOPEPTIDE RESISTANCE IN ENTEROCOCCI
    ARTHUR, M
    COURVALIN, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) : 1563 - 1571
  • [3] Evolution of antibiotic resistance
    Baquero, F
    Blazquez, J
    [J]. TRENDS IN ECOLOGY & EVOLUTION, 1997, 12 (12) : 482 - 487
  • [4] Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity
    Barbachyn, MR
    Hutchinson, DK
    Brickner, SJ
    Cynamon, MH
    Kilburn, JO
    Klemens, SP
    Glickman, SE
    Grega, KC
    Hendges, SK
    Toops, DS
    Ford, CW
    Zurenko, GE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) : 680 - 685
  • [5] Barriere JC, 1994, EXPERT OPIN INV DRUG, V3, P115
  • [6] Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
    Bauernfeind, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) : 639 - 651
  • [8] Novel C-2 substituted carbapenem derivatives part IV. Synthesis and biological activity of five membered heteroaromatic derivatives
    Branch, CL
    Burton, G
    Clarke, GJ
    Coulton, S
    Douglas, JD
    Eglington, AJ
    Guest, AW
    Hinks, JD
    Hird, NW
    Holland, RK
    Hunt, E
    Knott, SJ
    Moss, SF
    Naylor, A
    Pearson, MJ
    Takle, AK
    [J]. JOURNAL OF ANTIBIOTICS, 1998, 51 (02) : 210 - 220
  • [9] The chemistry and biological profile of trovafloxacin
    Brighty, KE
    Gootz, TD
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 : 1 - 14
  • [10] Emergent antibiotic resistance: health risks and economic impact
    Cassell, GH
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1997, 18 (04): : 271 - 274